Moleculin Capital Expenditures vs Change In Cash Analysis

MBRX Stock

USD 2.19 0.13 5.60%

Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech Capital Expenditures and its Change In Cash accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Capital Expenditures vs Change In Cash

Capital Expenditures vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moleculin Biotech Capital Expenditures account and Change In Cash. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Moleculin Biotech's Capital Expenditures and Change In Cash is -0.13. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Moleculin Biotech, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's Capital Expenditures and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Moleculin Biotech are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Capital Expenditures i.e., Moleculin Biotech's Capital Expenditures and Change In Cash go up and down completely randomly.

Correlation Coefficient

-0.13

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Moleculin Biotech to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Moleculin Biotech operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Change In Cash

Most indicators from Moleculin Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.At this time, Moleculin Biotech's Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.80 in 2024, whereas Selling General Administrative is likely to drop slightly above 6.9 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	260K	222K	127K	120.7K
Interest Income	306K	240K	1.2M	965.1K

Depreciation And Amortization Interest Income

Moleculin Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Property Plant And Equipment Net	Retained Earnings Total Equity
Total Assets		-0.51	0.65	0.73	0.99	0.8	0.74	-0.98	-0.75	0.72	0.98	0.75	0.07	0.98	0.83	-0.29	0.29	0.92	0.56	-0.74	0.98	-0.79	0.55	0.33	0.71	-0.87
Short Long Term Debt Total	-0.51		0.02	0.04	-0.54	-0.01	-0.22	0.5	-0.04	0.02	-0.5	-0.42	-0.29	-0.5	-0.2	0.25	-0.13	-0.18	-0.09	0.38	-0.49	0.32	-0.37	-0.34	-0.08	0.3
Other Current Liab	0.65	0.02		0.85	0.6	0.86	0.79	-0.58	-0.91	0.72	0.57	0.71	0.05	0.57	0.85	0.01	0.35	0.78	0.65	-0.73	0.58	-0.68	0.51	0.26	0.74	-0.75
Total Current Liabilities	0.73	0.04	0.85		0.65	0.78	0.86	-0.63	-0.89	0.96	0.62	0.8	0.27	0.62	0.87	-0.16	0.53	0.9	0.84	-0.82	0.65	-0.85	0.65	0.41	0.92	-0.85
Total Stockholder Equity	0.99	-0.54	0.6	0.65		0.78	0.66	-0.99	-0.68	0.63	0.99	0.68	-0.03	0.99	0.75	-0.23	0.15	0.88	0.43	-0.67	0.99	-0.71	0.44	0.21	0.6	-0.79
Net Tangible Assets	0.8	-0.01	0.86	0.78	0.78		0.66	-0.79	-0.94	0.72	0.79	0.56	-0.25	0.79	0.86	-0.22	0.22	0.89	0.52	-0.58	0.79	-0.66	0.35	0.14	0.68	-0.77
Current Deferred Revenue	0.74	-0.22	0.79	0.86	0.66	0.66		-0.63	-0.79	0.86	0.62	0.85	0.43	0.62	0.87	-0.16	0.58	0.78	0.81	-0.85	0.64	-0.77	0.8	0.59	0.85	-0.88
Net Debt	-0.98	0.5	-0.58	-0.63	-0.99	-0.79	-0.63		0.69	-0.6	-1.0	-0.59	0.07	-1.0	-0.75	0.25	-0.17	-0.88	-0.43	0.58	-1.0	0.7	-0.42	-0.21	-0.6	0.8
Retained Earnings	-0.75	-0.04	-0.91	-0.89	-0.68	-0.94	-0.79	0.69		-0.85	-0.68	-0.68	-0.03	-0.68	-0.96	0.33	-0.5	-0.9	-0.76	0.7	-0.7	0.79	-0.6	-0.42	-0.86	0.88
Accounts Payable	0.72	0.02	0.72	0.96	0.63	0.72	0.86	-0.6	-0.85		0.6	0.79	0.35	0.6	0.86	-0.33	0.6	0.86	0.86	-0.8	0.63	-0.87	0.7	0.52	0.93	-0.86
Cash	0.98	-0.5	0.57	0.62	0.99	0.79	0.62	-1.0	-0.68	0.6		0.59	-0.07	1.0	0.75	-0.25	0.17	0.88	0.42	-0.58	1.0	-0.69	0.41	0.21	0.6	-0.79
Non Current Assets Total	0.75	-0.42	0.71	0.8	0.68	0.56	0.85	-0.59	-0.68	0.79	0.59		0.43	0.59	0.77	-0.25	0.5	0.73	0.74	-1.0	0.61	-0.81	0.76	0.54	0.76	-0.78
Other Assets	0.07	-0.29	0.05	0.27	-0.03	-0.25	0.43	0.07	-0.03	0.35	-0.07	0.43		-0.07	0.23	-0.17	0.67	0.05	0.57	-0.39	-0.04	-0.49	0.72	0.76	0.49	-0.35
Cash And Short Term Investments	0.98	-0.5	0.57	0.62	0.99	0.79	0.62	-1.0	-0.68	0.6	1.0	0.59	-0.07		0.75	-0.25	0.17	0.88	0.42	-0.58	1.0	-0.69	0.41	0.21	0.6	-0.79
Common Stock Total Equity	0.83	-0.2	0.85	0.87	0.75	0.86	0.87	-0.75	-0.96	0.86	0.75	0.77	0.23	0.75		-0.44	0.64	0.91	0.84	-0.78	0.77	-0.88	0.78	0.62	0.92	-0.97
Common Stock Shares Outstanding	-0.29	0.25	0.01	-0.16	-0.23	-0.22	-0.16	0.25	0.33	-0.33	-0.25	-0.25	-0.17	-0.25	-0.44		-0.64	-0.3	-0.49	0.24	-0.27	0.45	-0.53	-0.67	-0.4	0.45
Non Current Liabilities Total	0.29	-0.13	0.35	0.53	0.15	0.22	0.58	-0.17	-0.5	0.6	0.17	0.5	0.67	0.17	0.64	-0.64		0.42	0.91	-0.51	0.2	-0.67	0.89	0.92	0.75	-0.66
Other Stockholder Equity	0.92	-0.18	0.78	0.9	0.88	0.89	0.78	-0.88	-0.9	0.86	0.88	0.73	0.05	0.88	0.91	-0.3	0.42		0.72	-0.75	0.89	-0.84	0.59	0.36	0.85	-0.92
Total Liab	0.56	-0.09	0.65	0.84	0.43	0.52	0.81	-0.43	-0.76	0.86	0.42	0.74	0.57	0.42	0.84	-0.49	0.91	0.72		-0.75	0.46	-0.86	0.9	0.8	0.94	-0.85
Short Long Term Debt	-0.74	0.38	-0.73	-0.82	-0.67	-0.58	-0.85	0.58	0.7	-0.8	-0.58	-1.0	-0.39	-0.58	-0.78	0.24	-0.51	-0.75	-0.75		-0.6	0.8	-0.74	-0.51	-0.76	0.77
Total Current Assets	0.98	-0.49	0.58	0.65	0.99	0.79	0.64	-1.0	-0.7	0.63	1.0	0.61	-0.04	1.0	0.77	-0.27	0.2	0.89	0.46	-0.6		-0.72	0.44	0.24	0.63	-0.81
Short Term Debt	-0.79	0.32	-0.68	-0.85	-0.71	-0.66	-0.77	0.7	0.79	-0.87	-0.69	-0.81	-0.49	-0.69	-0.88	0.45	-0.67	-0.84	-0.86	0.8	-0.72		-0.8	-0.67	-0.94	0.92
Common Stock	0.55	-0.37	0.51	0.65	0.44	0.35	0.8	-0.42	-0.6	0.7	0.41	0.76	0.72	0.41	0.78	-0.53	0.89	0.59	0.9	-0.74	0.44	-0.8		0.94	0.84	-0.83
Other Liab	0.33	-0.34	0.26	0.41	0.21	0.14	0.59	-0.21	-0.42	0.52	0.21	0.54	0.76	0.21	0.62	-0.67	0.92	0.36	0.8	-0.51	0.24	-0.67	0.94		0.7	-0.67
Property Plant And Equipment Net	0.71	-0.08	0.74	0.92	0.6	0.68	0.85	-0.6	-0.86	0.93	0.6	0.76	0.49	0.6	0.92	-0.4	0.75	0.85	0.94	-0.76	0.63	-0.94	0.84	0.7		-0.94
Retained Earnings Total Equity	-0.87	0.3	-0.75	-0.85	-0.79	-0.77	-0.88	0.8	0.88	-0.86	-0.79	-0.78	-0.35	-0.79	-0.97	0.45	-0.66	-0.92	-0.85	0.77	-0.81	0.92	-0.83	-0.67	-0.94

Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.2M	29.0M	84.1M	57.4M	38.2M	35.4M
Other Current Liab	164K	1.7M	2.2M	2.6M	4.2M	4.4M
Total Current Liabilities	3.6M	2.9M	3.6M	4.8M	6.8M	3.7M
Total Stockholder Equity	15.6M	17.8M	79.0M	52.2M	26.1M	28.9M
Net Tangible Assets	3.1M	4.4M	6.6M	67.8M	78.0M	81.9M
Net Debt	(10.4M)	(14.9M)	(70.7M)	(42.7M)	(23.0M)	(24.1M)
Retained Earnings	(39.6M)	(56.9M)	(72.8M)	(101.8M)	(131.6M)	(125.0M)
Accounts Payable	2.2M	1.1M	1.4M	2.1M	2.5M	1.5M
Cash	10.7M	15.2M	70.9M	43.1M	23.6M	22.4M
Non Current Assets Total	11.8M	11.8M	11.6M	11.8M	11.9M	11.4M
Cash And Short Term Investments	10.7M	15.2M	70.9M	43.1M	23.6M	22.4M
Common Stock Total Equity	21K	29K	46K	69K	79.4K	83.3K
Common Stock Shares Outstanding	452.5K	656.4K	1.8M	1.9M	2.0M	1.6M
Liabilities And Stockholders Equity	25.2M	29.0M	84.1M	57.4M	38.2M	35.4M
Non Current Liabilities Total	6.1M	8.4M	1.5M	412K	5.3M	2.9M
Other Stockholder Equity	55.1M	74.5M	151.7M	154.0M	157.7M	83.7M
Total Liab	9.7M	11.3M	5.1M	5.2M	12.1M	6.5M
Total Current Assets	13.5M	17.2M	72.5M	45.6M	26.3M	24.0M
Accumulated Other Comprehensive Income	31K	65K	41K	12K	(9K)	(8.6K)
Short Term Debt	103K	118K	96K	116K	100K	174.4K
Common Stock	21K	29K	46K	69K	33K	33.6K
Other Liab	1.4M	5.8M	8.2M	1.4M	1.6M	3.1M
Property Plant And Equipment Net	603K	685K	445K	678K	796K	512.3K
Retained Earnings Total Equity	(14.5M)	(26.4M)	(39.6M)	(56.9M)	(51.2M)	(48.7M)
Capital Surpluse	31.6M	40.6M	55.1M	74.7M	85.9M	48.7M
Other Current Assets	529K	2.0M	1.1M	1.6M	2.6M	2.8M
Property Plant And Equipment Gross	603K	685K	1.1M	678K	1.7M	1.8M
Property Plant Equipment	463K	603K	685K	445K	511.8K	412.9K
Net Invested Capital	15.6M	17.8M	79.0M	52.2M	26.1M	34.9M
Net Working Capital	9.9M	14.3M	68.9M	40.8M	19.5M	25.7M
Net Receivables	11K	1K	45K	22K	99K	104.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Moleculin Capital Expenditures vs Change In Cash Analysis

Capital Expenditures vs Change In Cash

Capital Expenditures vs Change In Cash Correlation Analysis

Correlation Coefficient

Capital Expenditures

Change In Cash

Moleculin Biotech fundamental ratios Correlations

Moleculin Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Moleculin Biotech fundamental ratios Accounts

Also Currently Popular

Additional Tools for Moleculin Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Short Long Term Debt	- 1.0	Non Current Assets Total
Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.98	Total Assets